

Small Cell Lung Cancer Consortium Meeting

9609 Medical Center Drive, Room TE110, Rockville, MD, May 1-2, 2024

Remote Access -WebEx

Wednesday, May 1, 2024

8:45 AM	Welcome	Kimryn Rathmell, Peter Ujhazy
9:00 AM	Keynote Address: Advancing the biology and therapeutics of SCLC: One patient at a time	Anish Thomas
Session 1: Biolo	Moderator: Kwon-Sik Park	
10:00 AM	Implication of BCAT1 and branched-chain amino acid metabolism in SCLC progression and detection	Kwon-Sik Park
10:15 AM	Stress-activated protein kinase signaling restricts subtype plasticity to suppress tumorigenesis in SCLC	Jackson Fatherree
10:30 AM	Investigating the roles of the epithelial-mesenchymal transition program in small cell lung cancer tumorigenesis and chemoradiation response	Triet Nguyen
10:45 AM	Murine models of relapsed small cell lung cancer to accelerate SCLC drug development and biomarker discovery.	Rajaa El Meskini
11:00 AM	Requirement for lineage transcription factors ASCL1 and NEUROD1 in mouse models of neuroendocrine prostate cancer	Jane Johnson
11:15 AM	Panel Discussion	All speakers and Andrea Ferris
11:30 AM	NCI opportunities for early career cancer researchers	Nastaran Zahir
12:15 - 1:45 PM	Lunch	

Session 2: Tumor Heterogeneity and Plasticity		Moderator: Abbie Ireland
1:45 PM	Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small cell lung cancer	Abbie Ireland
2:00 PM	SMARCA4 controls state plasticity in small cell lung cancer through regulation of neuroendocrine transcription factors and REST splicing	Esther Redin
2:15 PM	YAP1 defines a highly plastic, persister cell population in small cell lung cancer following relapse	C. Allison Stewart
2:30 PM	Convergent and divergent determinants of plasticity leading to histological transformation in lung cancer	Alvaro Quintanal- Villalonga
2:45 PM	Synchronous NEUROD1 degradation induces YAP1 transitions	Alexandru Buhimschi
3:00 PM	Kinase Suppressor of Ras 2 regulates small-cell lung carcinoma tumor propagating cells	Dianna Huisman
3:15 PM	The emerging role of deubiquitinating enzyme USP13 in lung cancer plasticity	Cecil Han
3:30 PM	Panel Discussion	All speakers and Kim Norris
3:45 - 4:15 PM	Break	
Session 3: New Therapy Targets		Moderator: Benjamin Lok
4:15 PM	MS023, a PRMT inhibitor, synergizes with DNA damaging agents in SCLC	Benjamin Lok
4:30 PM	AXL inhibition induces replication stress, cell death and immune responses in small cell lung cancer	Kavya Ramkumar
4:45 PM	Genome-wide analysis identifies Nuclear Factor 1C as a novel transcription factor and potential therapeutic target in small cell lung cancer	Haitao Wang
5:00 PM	Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer	Matthew Oser

5:15 PM Panel Discussion5:30 PM Adjourn

All speakers and Marcia Horn

Thursday, May 2, 2024

Session 4: Treatment Resistance		Moderator: Benjamin Morris
9:00 AM	Dissecting patterns of small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA	Benjamin Morris
9:15 AM	In vivo functional screens identify drivers of chemoresistance in small cell lung cancer	David MacPherson
9:30 AM	Delineating the mechanism of resistance to targeted therapy via cellular transdifferentiation	Priyanka Gopal
9:45 AM	Tumor initiation and therapy resistance in small-cell lung carcinoma	Deepan Chatterjee
10:00 AM	TNIK-induced chemoradiation resistance in small cell lung cancer	Dipanwita Dutta Chowdhury
10:15 AM	Panel Discussion	All speakers and Marcia Horn

10:30 - 10:45 AM *Break*

Session 5: Immunology and Immunotherapy		Moderator: Esra Akbay
10:45 AM	Nucleoside analog- 6-thio-2'-deoxyguanosine induces anti-tumor immune responses in SCLC	Buse Eglenen-Polat
11:00 AM	Identifying regulators of HLA repression in SCLC	Robert Szczepaniak Sloane
11:15 AM	NOTCH1 reverses immune suppression through STING and extends survival with immune checkpoint blockade in small cell lung cancer	Nitin Roper
11:30 AM	SOX9 promotes a non-neuroendocrine immunogenic state in small cell lung cancer (SCLC)	Maria Xu

11:45 AM	Cell plasticity by CRACD-EZH2 accelerates progression and immune evasion of small cell lung cancer	Jae-Il Park
12:00 PM	Panel Discussion	All speakers and Kim Norris
12:15 - 1:45 PM	Lunch	
1:45 PM	Panel: Promising Agents in Clinical Development	Charlie Rudin, Suzanne Forry, Anish Thomas, Eva Szabo, Lauren Byers, Ben Lok, Matt Oser, Andrea Ferris
2:15 PM	Panel: Current Scientific Opportunities/Next Steps in Translation	Lauren Byers, Trudy Oliver, Charlie Rudin, Ron Johnson, Peter Ujhazy, John Minna, David MacPherson, Kim Norris
2:45 PM	Adjourn	